

MONOCLONAL ANTIBODY DATASHEET



Clone F16 P2 D8 against human CYP2A6, CYP2A7 and CYP2A13


Product Description	Monoclonal antibody directed against human CYP2A6, CYP2A7 and CYP2A13. Supplied as hybridoma supernatant (unpurified).
Storage	Store at -20°C . Avoid repeated freeze-thaw cycles.
Intended Use	For laboratory (research) purposes only.
Isotype	IgG1, κ
Clone	F16 P2 D8
Immunogen	Ovalbumin-conjugated synthetic peptide; RNYTMSFLPR (amino-acids 485-494). [CYP2A6, CYP2A7 and CYP2A13 have the same C-terminal sequence.]
B Cell Donor	BALB-c mouse
Fusion Partner	Ag 8563
Positive Control	IHC: formalin-fixed, paraffin-embedded normal liver sections. Western blot: recombinant CYP (shown below @ 0.5 pmol per lane).

Applications		Recommended Usage Conditions (conditions should be optimised by the user)
ELISA	✓	Undiluted (titre 1/1000)
Western blot	✓	1/10 dilution
IHC	✓	1/5 dilution, antigen retrieval: microwave 20 min @ 800W in 10 mM citrate buffer, pH 6.0

Clinical significance	Results observed
Colorectal cancer	- CYP2A/2B showed low immunoreactivity in normal colon, colon cancer, and lymph node metastasis.
Ovarian cancer	- CYP2A/2B showed a higher frequency and a greater intensity of immunohistochemical staining in ovarian cancer compared with normal ovary. Absent/low CYP2A expression was associated with poor patient survival. CYP2A/2B shows an independent prognostic significance in ovarian cancer.
Breast cancer	- CYP2A/2B showed a higher frequency and a greater intensity of immunohistochemical staining in breast cancer compared with normal breast tissue.


References	<p>Kumarakulasingham M, Rooney PH, Dundas SR, Telfer C, Melvin WT, Curran S, Murray GI (2005). Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. <i>Clin Cancer Res.</i> 11: 3758-3765.</p> <p>Downie D, McFadyen MCE, Rooney PH, Cruickshank ME, Parkin DE, Miller ID, Telfer C, Melvin WT, Murray GI (2005) Profiling Cytochrome P450 Expression in Ovarian Cancer: Identification of Prognostic Markers. <i>Clin Cancer Res.</i> 11: 7369-7375.</p> <p>Murray G I, Patimalla S, Stewart K N, Miller I D & Heys S D (2010) Profiling the expression of cytochrome P450 in breast cancer. <i>Histopathology.</i> 57: 202-211.</p>
-------------------	--

**WESTERN BLOT OF
RECOMBINANT CYP450**



1. markers 2. CYP2A6

IMMUNOHISTOCHEMISTRY



Antibody staining of normal liver tissue